John V. Oyler (born 1968) is the co-founder and chief executive officer of BeOne Medicines (formerly BeiGene), a biotechnology company focused on oncology.
Early life and education Oyler grew up in Pittsburgh, Pennsylvania. He graduated from the Massachusetts Institute of Technology with a degree in mechanical engineering. He later earned an MBA from Stanford University.
Career Oyler began his career as a consultant at McKinsey & Company. In 1998, Oyler co-founded Telephia, a telecom research company. Nielsen Holdings acquired Telephia in 2007.
Following Telephia, Oyler co-founded BioDuro, a contract research organization, which was acquried by PPD in 2009.
In 2010, Oyler co-founded BeOne Medicines with Chinese biochemist Xiaodong Wang. The company has developed oncology medicines, including Tevimbra, a checkpoint inhibitor, and Brukinsa, a Bruton's tyrosine kinase inhibitor. As of 2025, BeOne has 11,000 employees.
See also BeiGene BeOne Medicines Xiaodong Wang (biochemist)
References
External links
John V. Oyler on LinkedIn